Saveme info

Funded by the European
Commission under the

FP7 NMP Theme
Project Acronym: SaveMe
Project ID: 263307
Start Date: 01-03-2011
Duration: 48 months
Project Budget: 14.04 Million Euro
Type: Collaborative project
End Date: 28-02-2015
Project Status: Execution


Concept PDF Print E-mail

An estimated 3.2 million new cancer cases and 1.7 million deaths per year in Europe define cancer as a crucial public health problem especially as these numbers are anticipated to increase. Thus, the SaveMe project is addressing major urgent needs for cancer diagnosis and treatment, by exploiting partners expertise, vast experience and most recent research achievements. SaveMe proposes the design and development of novel modular nanosystems platform integrating advanced functionalized nano-core particles and active agents. The modular platform will enable the design of diverse active nanosystems for diagnostic or therapeutic applications as defined by their active agent compositions: ligating only crucial active agents, at the optimized composition per application, while excluding other agents to minimize toxicity risks.

The innovative functionalized nanosystems together with in-silico, in-vitro and minimally in-vivo proof of concept for pancreatic cancer will serve as a background for further applications in different solid cancer therapies and diagnostics. The proposed modular active nanosystems platform can be implemented for the management of various solid tumors, as per their Somatostatin and Galectin-1 receptors (SSTR and Gal-1/tPA)  selective expression.

The novel modular platform for targeted therapeutics, imaging diagnosis, and guided surgery, is a breakthrough in cancer treatment.

The consortium consists of nineteen partners from seven EU Member States (Germany, UK, Sweden, Belgium, Spain, Austria and Italy), one Associated State (Israel) and one ICPC (Russia). The consortium includes 3 SMEs, 2 large Industries, 3 hospitals and 11 research institutes and universities. The partners come from different cultural backgrounds but more important from different scientific and technological disciplines: Nanochemistry and nanotechnology, Industrial nanochemistry, biotechnology and nanobiotechnology, in-silico modeling of biomechanics, toxicology and pharmacology, in-vitro, in-vivo and ex vivo studies, imaging, degradomics, molecular and cell biology.